Literature DB >> 7540526

Treatment of vasculitic leg ulcers in connective tissue disease with iloprost.

D J Veale1, A H Muir, K D Morley, J J Belch.   

Abstract

Leg ulcers are a recognised manifestation of cutaneous vasculitis in connective tissue diseases (CTDs) including rheumatoid arthritis (RA). Iloprost a stable prostacyclin analogue has been successfully used to treat Raynaud's phenomenon and digital ulcers associated with CTD's. Our aim was to assess iloprost in the treatment of vasculitic leg ulcers in CTD. In this paper we describe eight cases of vasculitic leg ulceration in association with RA and CTD, treated with intravenous iloprost. The iloprost was administered for 6-8 hours daily and continued for 21-28 days. Immunosuppressive therapy was required in three patients with severe necrotising vasculitis (RAnv). Complete ulcer healing was achieved in four patients within 6 weeks of commencing therapy while rapid improvement occurred in the other four patients. This suggests that iloprost may be useful as an adjunct to therapy for vasculitic leg ulcers. A double-blind placebo controlled study of iloprost therapy for RA leg ulcers is under way.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540526     DOI: 10.1007/bf02214941

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  4 in total

1.  LEG ULCERS COMPLICATING RHEUMATOID ARTHRITIS.

Authors:  M WILKINSON; J KIRK
Journal:  Scott Med J       Date:  1965-04       Impact factor: 0.729

2.  Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

Authors:  N J McHugh; M Csuka; H Watson; G Belcher; A Amadi; E F Ring; C M Black; P J Maddison
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

3.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

4.  Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.

Authors:  D A Yardumian; D A Isenberg; M Rustin; G Belcher; M L Snaith; P M Dowd; S J Machin
Journal:  Br J Rheumatol       Date:  1988-06
  4 in total
  1 in total

1.  The safety of iloprost in systemic sclerosis in a real-life experience.

Authors:  S Bellando-Randone; C Bruni; G Lepri; G Fiori; F Bartoli; M L Conforti; A Moggi-Pignone; S Guiducci; D Giuggioli; M Colaci; A Spinella; C Ferri; M Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2018-02-22       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.